title: Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).
abstract: BACKGROUND
  Limited experience is available on the feasibility and efficacy of autologous stem-cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) beyond 65 years.
  
  
  METHODS
  We analysed 712 patients with MCL treated with ASCT from 2000 to 2007 and reported to the European Group for Blood and Marrow Transplantation registry. Patients>65 years were compared with patients<65 years for the end points non-relapse mortality (NRM), relapse incidence, progression-free survival (PFS), and overall survival (OS).
  
  
  RESULTS
  Seventy-nine patients were ≥65 years old. Median time from diagnosis to ASCT was longer in the elderly patients (11 versus 9 months, P=0.005); they had more commonly received at least two treatment lines (62.0% versus 47.9%, P=0.02) and were less commonly in first complete remission at ASCT (35.4% versus 51.2%, P=0.002). Median follow-up after ASCT was 19 and 25 months, respectively. NRM was comparable at 3 months (3.8% versus 2.5%) and at 5 years (5.6% versus 5.0%). There were no differences in relapse rate (66% versus 55% at 5 years), PFS (29% versus 40%) and OS (61% versus 67%) between both populations of patients.
  
  
  CONCLUSIONS
  ASCT beyond 65 years of age is feasible in selected patients with MCL and results in similar disease control and survival as in younger patients.
authors.affiliation: Department of Medicine, Institute of Clinical Medicine, University of Eastern Finland and Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
authors.forename: E
authors.initials: E
authors.lastname: Jantunen
authors.affiliation: EBMT Lymphoma Working Party, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Canals
authors.affiliation: Department of Hematology, Hopital de Purpan, CHU, Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.affiliation: Department of Hematology, University College London Hospital, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Thomson
authors.affiliation: Department of Hematology, Hopital Haut-Leveque, CHU Bordeaux, Pessac, France.
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.affiliation: Department of Hematology, Hopital Necker, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Buzyn
authors.affiliation: Department of Hematology, Cliniques Universitaires St Luc, Brussels, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Ferrant
authors.affiliation: Department of Hematology, Centre Leon Bernard, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Biron
authors.affiliation: Department of Hematology, Addenbrookes Hospital, Cambridge, UK.
authors.forename: C
authors.initials: C
authors.lastname: Crawley
authors.affiliation: Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Schattenberg
authors.affiliation: EBMT Data Office, Faculté de Médecine Saint-Antoine, Paris, France.
authors.forename: J J
authors.initials: JJ
authors.lastname: Luan
authors.affiliation: Department of Hematology, Centre Henri Becquerel, Rouen, France.
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.affiliation: Department of Hematology, Hotel Dieu, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.affiliation: Department of Hematology, Hague Hospital, The Hague, The Netherlands.
authors.forename: P W
authors.initials: PW
authors.lastname: Wijermans
authors.affiliation: Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Dreger
authors.affiliation: Department of Hematology, Addenbrookes Hospital, Cambridge, UK; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: ana.sureda@addenbrookes.nhs.uk.
authors.forename: A
authors.initials: A
authors.lastname: Sureda
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D020522:Lymphoma, Mantle-Cell / Q000401:mortality* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D033581:Stem Cell Transplantation / Q000401:mortality*; D014182:Transplantation, Autologous